Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Rybowski

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|July 5, 2012
Women's attitudes towards monthly bleeding: results of a global population-based surveyAnne Szarewski, Ariane von Stenglin, Sarah Rybowski
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|August 6, 2016
A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive ageLynn Borgatta, Kai J Buhling, Sarah Rybowski, et al.
Obstetrics and Gynecology|November 19, 2013
Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trialAnita Nelson, Dan Apter, Brian Hauck, et al.
Plos One|September 18, 2015
The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III TrialKristina Gemzell-Danielsson, Dan Apter, Brian Hauck, et al.
Fertility and Sterility|March 27, 2016
A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implantDan Apter, Paula Briggs, Marjo Tuppurainen, et al.
Drugs - Real World Outcomes|September 13, 2022
Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with AbemaciclibEmily Nash Smyth, Julie Beyrer, Kimberly R Saverno, et al.
Advances in Radiation Oncology|February 24, 2026
Utilization and Safety of Concurrent Use of Abemaciclib and Radiation Therapy Among Patients With HR+, HER2- Metastatic Breast Cancer in the Real-World SettingWambui Gathirua-Mwangi, Sangmi Kim, Holly Martin, et al.
The Oncologist|October 17, 2024
Real-world outcomes in patients with brain metastases secondary to HR+/HER2- MBC treated with abemaciclib and local intracranial therapyWambui Gathirua-Mwangi, Holly Martin, Dan He, et al.
Advances in Therapy|March 30, 2023
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical PracticeAlistair Ring, Meghan Karuturi, Emily Nash Smyth, et al.
Drugs - Real World Outcomes|September 29, 2023
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical PracticeAlistair Ring, Meghan Karuturi, Emily Nash Smyth, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|July 5, 2012
Women's attitudes towards monthly bleeding: results of a global population-based surveyAnne Szarewski, Ariane von Stenglin, Sarah Rybowski
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|August 6, 2016
A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive ageLynn Borgatta, Kai J Buhling, Sarah Rybowski, et al.
Obstetrics and Gynecology|November 19, 2013
Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trialAnita Nelson, Dan Apter, Brian Hauck, et al.
Plos One|September 18, 2015
The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III TrialKristina Gemzell-Danielsson, Dan Apter, Brian Hauck, et al.
Fertility and Sterility|March 27, 2016
A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implantDan Apter, Paula Briggs, Marjo Tuppurainen, et al.
Drugs - Real World Outcomes|September 13, 2022
Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2- Metastatic Breast Cancer Treated with AbemaciclibEmily Nash Smyth, Julie Beyrer, Kimberly R Saverno, et al.
Advances in Radiation Oncology|February 24, 2026
Utilization and Safety of Concurrent Use of Abemaciclib and Radiation Therapy Among Patients With HR+, HER2- Metastatic Breast Cancer in the Real-World SettingWambui Gathirua-Mwangi, Sangmi Kim, Holly Martin, et al.
The Oncologist|October 17, 2024
Real-world outcomes in patients with brain metastases secondary to HR+/HER2- MBC treated with abemaciclib and local intracranial therapyWambui Gathirua-Mwangi, Holly Martin, Dan He, et al.
Advances in Therapy|March 30, 2023
Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical PracticeAlistair Ring, Meghan Karuturi, Emily Nash Smyth, et al.
Drugs - Real World Outcomes|September 29, 2023
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical PracticeAlistair Ring, Meghan Karuturi, Emily Nash Smyth, et al.
Pageof 2